^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Uterine Cancer

Related cancers:
20h
Gene Expression Analysis for Uterine Cervix and Corpus Cancer Characterization. (PubMed, Genes (Basel))
In summary, this study provides valuable insights into the molecular mechanisms of uterine cervix and corpus cancers. The newly identified gene signatures demonstrate robust predictive capabilities, guiding future research in cancer diagnosis and treatment methodologies.
Journal
|
ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1)
1d
Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma. (PubMed, Anticancer Res)
Expression levels of MMP2 and MMP9 were upregulated in malignant uLMS tumors when compared with those in benign uterine leiomyoma tumors. Increased MMP2 expression might promote uLMS invasion and migration. MMP9 overexpression might be related to uLMS occurrence; however, it protects against uLMS invasion and metastasis. MMP2 and MMP9 may be potential predictors of uLMS cell proliferation, metastasis, and prognosis. These findings could be helpful in developing new strategies for diagnosing and treating uLMS.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
MMP9 overexpression
1d
Enhanced glycolysis in the myometrium with ectopic endometrium of patients with adenomyosis: a preliminary study. (PubMed, Gynecol Endocrinol)
Besides, increased glucose consumption and lactate production were observed in myometrium with ectopic endometrium. We concluded that altered glycolytic phenotype of the myometrium with ectopic endometrium in women with adenomyosis may contribute the development of adenomyosis.
Journal
|
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • PKM (Pyruvate Kinase M1/2)
1d
PFAS Modulate Osmotic Signaling Independent of Gravimetric Changes in the Rat Uterus. (PubMed, Toxics)
These results demonstrate that in vitro estrogen screens or impacts in fish may show different responses from direct impacts on mammalian uterine weight as assessed with the uterotrophic assay. This study also builds out new mechanisms that may contribute to understanding of carcinogenic changes seen in the uterus after PFAS exposure.
Preclinical • Journal
|
ER (Estrogen receptor)
4d
Role of microRNA in Sex Steroid Hormones Signaling and Its Effect in Regulation of Endometrial, Ovarian, and Cervical Cancer: A Literature Review. (PubMed, Cureus)
Recent research has shown that miRNAs can modify hormone signaling pathways and affect the expression of sex steroid hormone receptors. Our goal in this literature review is to present an overview of current knowledge regarding the role of miRNAs in cancers regulated by sex steroid hormone pathways, as well as to identify particular miRNA targets for hormonal therapy.
Review • Journal
|
PGR (Progesterone receptor)
7d
Enrollment change • Metastases
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
7d
GyneRep: Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (clinicaltrials.gov)
P1, N=24, Active, not recruiting, University Health Network, Toronto | Not yet recruiting --> Active, not recruiting | Initiation date: Dec 2023 --> Mar 2024
Enrollment closed • Trial initiation date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
carboplatin • paclitaxel • lunresertib (RP-6306)
8d
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer (clinicaltrials.gov)
P=N/A, N=30, Recruiting, Rutgers, The State University of New Jersey | Trial primary completion date: Dec 2023 --> May 2024
Trial primary completion date
8d
Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas. (PubMed, Mod Pathol)
All cases showed high NR4A3 RNA expression levels and NOR1 (NR4A3) nuclear staining similar to salivary gland acinic cell carcinoma and a subset of extraskeletal myxoid chondrosarcomas harboring NR4A3 rearrangement. NOR1 (NR4A3) immunohistochemistry may serve as a useful diagnostic marker of NR4A3 fusion-positive gynecologic leiomyosarcomas.
Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3) • MME (Membrane Metalloendopeptidase) • SLCO5A1 (Solute Carrier Organic Anion Transporter Family Member 5A1)
10d
A Novel EPC1::KDM2B Fusion in High-grade Endometrial Stromal Sarcoma. (PubMed, Int J Gynecol Pathol)
Immunohistochemistry showed strong and diffuse cyclin D1 positivity while CD10, WT1, DOG1, CD117, CD34, CD99, S100, MelanA, SMA, desmin, and h-caldesmon were negative. The tumor was confined to the uterus and no recurrence has been detected thus far, albeit with a short follow-up interval of 9 mo.
Journal • Stroma
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CCND1 (Cyclin D1) • WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • MME (Membrane Metalloendopeptidase) • ANO1 (Anoctamin 1) • CD99 (CD99 Molecule)
10d
SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=111, Terminated, Seagen Inc. | Trial completion date: Mar 2026 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Mar 2024; Study closed due to portfolio prioritization
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
SGN-STNV
10d
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey. (PubMed, J Gynecol Oncol)
Real-world data suggest that many healthcare professionals still do not easily prescribe HRT for gynecological cancer survivors and BRCA mutation carriers after RRSO. Further efforts are required to implement the use of HRT in clinical practice and to support both clinicians in recommending HRT and patients in accepting it.
Journal • BRCA Biomarker
|
BRCA (Breast cancer early onset)
|
BRCA mutation
11d
The Analysis of ceRNA Networks and Tumor Microenvironment in Endometrial Cancer. (PubMed, J Cancer)
A receiver operating characteristic curve was constructed to predict patient outcomes. Using a nomogram, we predicted the outcomes of patients with UCEC Furthermore, we revealed its significance in improving clinical management.
Journal
|
PPARGC1A (PPARG Coactivator 1 Alpha) • PPARGC1B (PPARG Coactivator 1 Beta) • TEAD1 (TEA Domain Transcription Factor 1)
11d
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation. (PubMed, Genes Chromosomes Cancer)
Nine tumors were tested with Nanocind CINSARC® signature and all were classified in low risk of recurrence. We propose, based on our observations, a diagnostic approach of these challenging lesions.
Journal
|
TP53 (Tumor protein P53) • FH (Fumarate Hydratase)
|
TP53 deletion • FH deletion
11d
A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma. (PubMed, Sci Rep)
Analysis of immune infiltration revealed a negative correlation between TK1 and CD8 + T cells, macrophages, and dendritic cells. In vitro experiments, TK1 knockdown resulted in the inhibition of proliferation, migration, invasion and EMT in UCEC cell lines.
Journal
|
CD8 (cluster of differentiation 8) • TK1 (Thymidine Kinase 1)
|
TK1 expression
11d
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients (clinicaltrials.gov)
P1, N=56, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting
Enrollment closed
|
Xpovio (selinexor)
14d
Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy. (PubMed, Curr Cancer Drug Targets)
Our analysis preliminarily describes the complex function of CMPK2 in cancer progression and immune microenvironment highlighting its potential as a diagnostic and therapeutic target for immunotherapy.
Journal • IO biomarker • Pan tumor
|
NLRP3 (NLR Family Pyrin Domain Containing 3)
14d
The Spectrum of Fusions Occurring in Non-Smooth Muscle Mesenchymal Uterine Tumors: A Review of the Current Knowledge. (PubMed, Arch Pathol Lab Med)
This can be related to the rare aberrations with a limited number of reported cases. Additionally, even well-known aberrations considered as specific for a certain distinct entity can occur in more lesions, the biological behavior and clinical significance of which can differ substantially.
Review • Journal
|
KAT6A (Lysine Acetyltransferase 6A)
15d
Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H. (PubMed, Genes Chromosomes Cancer)
Additionally, all tumors presented unique mutations in endometrial cancer-associated genes such as ARID1A and PIK3CA. In conclusion, we demonstrated clonal origin and genomic diversity in a Lynch syndrome-associated endometrial cancer, suggesting the importance of evaluating multiple sites in Lynch syndrome patients with synchronous tumors.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • MLH1 (MutL homolog 1)
|
PIK3CA mutation • ARID1A mutation
16d
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
P1/2, N=54, Not yet recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Sep 2023 --> Mar 2024
Trial initiation date • Combination therapy
|
cisplatin • Trodelvy (sacituzumab govitecan-hziy)
17d
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia (clinicaltrials.gov)
P=N/A, N=90, Recruiting, Hadassah Medical Organization | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date
17d
Alpha-fetoprotein producing endometrioid carcinoma arising in an adenomyoma of the uterus. (PubMed, Med Mol Morphol)
The concept of retrodifferentiation or neometaplasia suggests that "endometrioid carcinoma with yolk sac tumor differentiation" or "endometrioid carcinoma with a primitive phenotype" may serve as more fitting terms for the diverse spectrum of AFP-producing neoplasms in the endometrium. In conclusion, this case underscores the diagnostic challenges posed by AFP-ECs arising from adenomyomas and emphasizes the need for refining the nomenclature and classification of AFP-producing neoplasms within the endometrium.
Journal
|
AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4)
19d
Potential bioactive compound and hub gene identification of endometrial carcinoma using systems biology. (PubMed, J Biomol Struct Dyn)
Low RMSD and SASA (Solvent accessible surface area), high RMSF, High hydrogen bonds, between Asarone and MSH2 demonstrated their potency as endometrial cancer inhibitor compounds. Based on these analyses we infer that the bioactive substances originating from medicinal plants may be an effective treatment for endometrial cancer.Communicated by Ramaswamy H. Sarma.
Journal
|
MSH2 (MutS Homolog 2)
21d
A landscape of patient-derived cancer-associated fibroblast signals in endometrial cancers. (PubMed, Am J Cancer Res)
We demonstrate that endometrial CAFs can be cultured in an enzymatic-digestion-independent manner, and their signaling landscape can be mapped toward understanding CAF-TME dialogue. Our data will help unearth the functional relevance of endometrial CAFs in the context of clinical outcomes and designing CAF-inclusive therapy in the future.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin) • FAP (Fibroblast activation protein, alpha) • PVR (PVR Cell Adhesion Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • THY1 (Thy-1 membrane glycoprotein) • MMP1 (Matrix metallopeptidase 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • S100A4 (S100 calcium binding protein A4)
|
CD8 positive • CD44 expression • CXCL12 expression • VIM expression • EPCAM expression
21d
Endometrial cytological findings for a mesonephric-like endometrial adenocarcinoma: A case report. (PubMed, Diagn Cytopathol)
The tumor was invasive and extended beyond one-half of the muscle layer with a high degree of vascular invasion. In conclusion, we need to focus on the various shapes of the cell aggregate, nuclear grooves, and intranuclear pseudo-inclusions of tumor cells to distinguish an ML-EAC from other endometrial carcinomas in endometrial cytology.
Journal
|
PGR (Progesterone receptor) • NKX2-1 (NK2 Homeobox 1) • GATA3 (GATA binding protein 3)
21d
Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue. (PubMed, Gynecol Oncol)
An important caveat for future liquid biopsy/DNA-based cancer diagnostics is the repertoire of shared and distinct mutation profiles between histologically unremarkable and EndoCA tissues. The lack of selection pressure between functional and non-functional mutations in histologically unremarkable uterine tissue may offer a glimpse into an unrecognized EndoCA protective mechanism.
Journal
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • NOTCH1 (Notch 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
PIK3CA mutation
23d
Prevalence of fibroblast growth factor receptor (FGFR) alterations (alts) and programmed death-ligand 1 (PD-L1) expression (exp) in Chinese solid tumor patients (pts) (AACR 2024)
BALVERSA (erdafitinib), a selective pan-FGFR kinase inhibitor, has shown clinical activity against FGFR altered solid tumors in pts who exhausted standard treatment options... The large Chinese solid tumor cohort analysis showed comparable FGFR alts prevalence between Chinese and Western population. Differences in relationship between FGFR alts and PD-L1 expression across tumor types reflect the differential role of predominant FGFR types in each tumor type.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • PD-L1 overexpression • FGFR1 amplification • FGFR1 expression
|
PD-L1 IHC 22C3 pharmDx • MSK-IMPACT
|
Balversa (erdafitinib)
24d
SAVE: Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (clinicaltrials.gov)
P3, N=188, Recruiting, University of Utah | Active, not recruiting --> Recruiting | N=108 --> 188 | Trial completion date: Sep 2024 --> Oct 2029 | Trial primary completion date: Dec 2021 --> Nov 2026
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
24d
Journal
|
LGALS3 (Galectin 3)
|
LGALS3 elevation
25d
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer. (PubMed, Cancer Sci)
In the MMRd without LS group, the 5-year OS rate was significantly worse in seven patients with an aberrant p53 expression pattern than in those with p53 WT (53.6% vs. 93.9%, log-rank test; p = 0.0016). These results suggest that p53 abnormalities and pathogenic germline variants in MMR genes could be potential biomarkers for the molecular classification of EC with MMRd.
Journal • Mismatch repair
|
TP53 (Tumor protein P53) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
TP53 wild-type • TP53 expression
25d
ACSL1-Mediated Fatty Acid β-Oxidation Enhances Metastasis and Proliferation in Endometrial Cancer. (PubMed, Front Biosci (Landmark Ed))
This study indicates that ACSL1 regulates the AMPK/CPT1C/ATP pathway, which induces fatty acid β-oxidation, promotes proliferation and migration, and then leads to the malignant progression of EC.
Journal
|
ACSL1 (Acyl-CoA Synthetase Long Chain Family Member 1)
27d
Genomic Testing and Resulting Medical Decisions (clinicaltrials.gov)
P=N/A, N=1000, Recruiting, Arbeitsgemeinschaft medikamentoese Tumortherapie | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
Trial completion date • Trial primary completion date
|
TMB (Tumor Mutational Burden)
30d
Enrollment open • Metastases
|
AKT1S1 (AKT1 Substrate 1)
|
ipatasertib (RG7440) • megestrol
1m
Metastasis of Clear Cell Renal Cell Carcinoma to Uterine Leiomyoma: First Case Report and Review of Literature. (PubMed, Int J Surg Pathol)
The pathologic exam of the specimen was consistent with metastatic clear cell RCC (1.2 cm) to uterine leiomyoma, confirmed with keratin, vimentin, CD10, CA9, and PAX8 immunohistochemistry. The patient's postoperative course was uneventful, and no new lesions were identified at follow-up during the past 6 months.
Review • Journal
|
CA9 (Carbonic anhydrase 9) • VIM (Vimentin) • MME (Membrane Metalloendopeptidase) • PAX8 (Paired box 8)
1m
The Prognostic Value and Clinical Significance of lncRNA SNHG5 Expression in Patients with Multiple Malignancies: A Bioinformatic and Meta-Analysis. (PubMed, Curr Cancer Drug Targets)
These results suggest that lncRNA SNHG5 may serve as an adverse prognostic biomarker in several human cancers. Further investigations are needed to better understand the underlying mechanisms that link lncRNA SNHG5 to multiple malignancies.
Clinical • Retrospective data
|
SNHG5 (Small Nucleolar RNA Host Gene 5)
1m
Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma. (PubMed, Sci Rep)
The two necroptosis-related miRNAs used in this study may serve as valuable prognostic markers for UCEC patients, and are associated with immune cell infiltration. This suggests that necroptosis may be involved in the development of UCEC through its interaction with immune responses.
Journal
|
CD8 (cluster of differentiation 8) • MIR200A (MicroRNA 200a) • MIR7 (MicroRNA 7) • MIR141 (MicroRNA 141) • MIR210 (MicroRNA 210) • MIR425 (MicroRNA 425) • MIR29A (MicroRNA 29a) • MIR383 (MicroRNA 383)
1m
New P2 trial
|
doxorubicin hydrochloride • ifosfamide
1m
NCI-2017-01888: Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer (clinicaltrials.gov)
P1, N=15, Active, not recruiting, University of Colorado, Denver | Trial completion date: Nov 2023 --> Nov 2024
Trial completion date
1m
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MUC16 (Mucin 16, Cell Surface Associated)
|
HER-2 negative • PGR expression
|
gemcitabine • Elahere (mirvetuximab soravtansine-gynx)
1m
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers (clinicaltrials.gov)
P1, N=39, Completed, AA Secord | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab)
1m
Detection of metastatic lymph node and sentinel lymph node mapping ​using mannose receptor targeting in in vivo mouse and rabbit uterine cancer models. (PubMed, Int J Surg)
MSA-ICG was able to distinguish metastatic LN for an extended period due to its specific tumor-associated macrophage-targeting property. Therefore, it may be a more distinguishable tracer for identifying metastatic LNs and SLNs during uterine cancer surgery. Further research is needed to confirm these results.
Preclinical • Journal • Metastases
|
MRC1 (Mannose Receptor C-Type 1)
|
MRC1 expression
1m
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov)
P2, N=84, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)